PACS Group's stock soared 25.36% during intraday trading on Tuesday, marking a significant surge in the healthcare company's share price.
The dramatic rise follows the company's release of first-quarter 2026 financial results that substantially exceeded analyst expectations. PACS Group reported quarterly earnings of $0.50 per share, beating the consensus estimate of $0.40, while revenue reached $1.42 billion, surpassing estimates of $1.36 billion and representing an 11.2% year-over-year increase.
Investor sentiment was further boosted by the company's decision to raise its full-year 2026 adjusted EBITDA guidance to $605-$625 million from the previous range of $555-$575 million. Additionally, the board approved a new $250 million share repurchase authorization. Company leadership credited the strong quarterly performance to improved occupancy rates, increased skilled mix, and benefits from incentive programs at both newer and existing facilities.
Comments